Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does GLIMEPIRIDE Cause Condition aggravated? 114 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 114 reports of Condition aggravated have been filed in association with GLIMEPIRIDE (Glimepiride). This represents 2.1% of all adverse event reports for GLIMEPIRIDE.

114
Reports of Condition aggravated with GLIMEPIRIDE
2.1%
of all GLIMEPIRIDE reports
36
Deaths
71
Hospitalizations

How Dangerous Is Condition aggravated From GLIMEPIRIDE?

Of the 114 reports, 36 (31.6%) resulted in death, 71 (62.3%) required hospitalization, and 32 (28.1%) were considered life-threatening.

Is Condition aggravated Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for GLIMEPIRIDE. However, 114 reports have been filed with the FAERS database.

What Other Side Effects Does GLIMEPIRIDE Cause?

Hypoglycaemia (1,403) Blood glucose increased (446) Acute kidney injury (339) Drug ineffective (339) Diarrhoea (257) Blood glucose decreased (232) Lactic acidosis (219) Glycosylated haemoglobin increased (214) Diabetes mellitus inadequate control (213) Hypoglycaemic coma (187)

What Other Drugs Cause Condition aggravated?

TOFACITINIB (16,925) INFLIXIMAB (16,616) DUPILUMAB (16,459) ETANERCEPT (15,897) METHOTREXATE (14,938) ADALIMUMAB (13,527) PREDNISONE (10,751) INFLIXIMAB-DYYB (10,275) HYDROXYCHLOROQUINE (8,848) RITUXIMAB (8,627)

Which GLIMEPIRIDE Alternatives Have Lower Condition aggravated Risk?

GLIMEPIRIDE vs GLIMEPIRIDE\ROSIGLITAZONE GLIMEPIRIDE vs GLIPIZIDE GLIMEPIRIDE vs GLIVEC GLIMEPIRIDE vs GLOFITAMAB GLIMEPIRIDE vs GLOFITAMAB-GXBM

Related Pages

GLIMEPIRIDE Full Profile All Condition aggravated Reports All Drugs Causing Condition aggravated GLIMEPIRIDE Demographics